{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.9","value":"284"},{"groupId":"OG001","spread":"59.3","value":"241"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Nanatinostat (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"101.2","value":"291"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Nanatinostat (Cycle 6 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.6","value":"1470"},{"groupId":"OG001","spread":"56.8","value":"1410"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"M1 Metabolite (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.2","value":"3750"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"M1 Metabolite (Cycle 6 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.9","value":"263"},{"groupId":"OG001","spread":"66.2","value":"248"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"M2 Metabolite (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"168.2","value":"335"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"M2 Metabolite (Cycle 6 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.9","value":"21600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Ganciclovir (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"33400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Ganciclovir (Cycle 6 Day 1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Defined as the area under the concentration-time curve from time 0 to the last measurable plasma concentration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients with relapsed or refractory EBV-positive lymphoma or lymphoproliferative disorder treated with nanatinostat 20 mg once daily (QD) on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG000","title":"Combination Therapy (EBV-Associated Lymphoid Malignancy)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week","id":"OG001","title":"Monotherapy (EBV-Positive Peripheral T-Cell Lymphoma)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Defined as all patients (pts) who received at least 1 dose of study drug on Cycle 1 Day 1 and had at least 1 valid PK concentration. AUC0-t data were previously generated for subset of 50 pts, 4 of whom reached Cycle 6 at time of analysis. As prespecified by the analysis plan, combination therapy cohorts were combined since AUC for small molecules should not be affected by lymphoma subtype. PK samples from remaining pts were not tested due to sponsor company closure soon after study termination.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 6 Day 1 at pre-dose and 1, 2, 4, and 6 hours post-dose (each cycle was 28 days)","title":"Pharmacokinetic Parameter - Area Under the Plasma Concentration-Time Curve [AUC0-t]","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}